Pancreatic Cancer Clinical Trials in Cleveland

Showing 121-140 of 159 trials

Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study

NCT02345460

This phase II trial studies how well combination chemotherapy works in treating patients with pancreatic cancer before undergoing surgery. Drugs used in chemotherapy, such as irinotecan hydrochloride, oxaliplatin, leucovorin calcium, and fluorouracil (FOLFIRINOX), work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving more than one drug (combination chemotherapy) before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.

Pancreatic AdenocarcinomaPoorly Differentiated Malignant NeoplasmResectable Pancreatic Cancer+6 more

Case Comprehensive Cancer Center1 participantsStarted Sep 2015

Cleveland, Ohio, United States

COMPLETEDPhase 3< 1 mile

OSI-774 (Tarceva) Plus Gemcitabine in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer.

NCT00040183

The purpose of this study is to determine if OSI-774 will improve overall survival when combined with a standard dose of the chemotherapy drug gemcitabine, to individuals with pancreatic cancer.

Pancreatic Cancer

OSI Pharmaceuticals569 participantsStarted Nov 2001

Tucson, Arizona, United States • Springdale, Arkansas, United States • Berkeley, California, United States +137 more locations

Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study

OSI-774 (Tarceva) Plus Gemcitabine in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer.

Pancreatic Cancer Trials in Other Cities

Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy

Biological Markers in Patients With Pancreatic Cancer Experiencing Weight Loss

Erlotinib and Gemcitabine With or Without Panitumumab in Treating Patients With Metastatic Pancreatic Cancer

Ganitumab and Gemcitabine Hydrochloride Followed by Radiation Therapy, Ganitumab, Capecitabine, and Maintenance Therapy in Treating Patients With Locally Advanced Cancer of the Pancreas

Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting

Safety and Efficacy of Combination Listeria/GVAX Immunotherapy in Pancreatic Cancer

A Study Evaluating IPI-926 in Combination With Gemcitabine in Patients With Metastatic Pancreatic Cancer

Combination Chemotherapy and Radiation Therapy in Treating Patients With Pancreatic Cancer

AZD6244 vs. Capecitabine (Xeloda®) in Patients With Advanced or Metastatic Pancreatic Cancer, Who Have Failed First Line Gemcitabine Therapy

Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic Cancer

Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer

Gemcitabine Alone or in Combination With Other Chemotherapy Drugs in Treating Patients With Metastatic Cancer of the Pancreas

S9924 R115777 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Gemcitabine With or Without Dalteparin in Treating Patients With Unresectable or Metastatic Pancreatic Cancer

A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types

A Phase I/II Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Gemcitabine in Cancer Patients

Safety and Efficacy Study of PRI-724 Plus Gemcitabine in Subjects With Advanced or Metastatic Pancreatic Adenocarcinoma

Other Conditions in Cleveland